Axogen, Inc. (AXGN) Earnings Call Analysis

NASDAQ · Healthcare · Medical Devices

14/25

Growth 3 Margin 3 Expansion 3 Platform 1 Financial 4

latest quarter score

Earnings Reports

14
Axogen (AXGN) Q2 2026: Breast Segment Drives 47% Growth, Reshaping Margin Mix
July 29, 2026
17
Axogen (AXGN) Q1 2026: Coverage Expands to 86%, Unlocking New Nerve Repair Adoption
April 28, 2026
20
Axogen (AXGN) Q4 2025: Avance BLA Approval Unlocks 12-Year Exclusivity, Elevates Margin Pathway
February 25, 2026
21
Axogen (AXGN) Q3 2025: Nerve Repair Revenue Jumps 23.5% as BLA Milestone Nears
October 29, 2025
21
Axogen (AXGN) Q2 2025: High-Potential Account Productivity Up 21%, Fueling Durable Nerve Care Growth
August 05, 2025
14
Axogen (AXGN) Q1 2025: High-Potential Account Productivity Up 24%, Accelerating Standard of Care Push
July 06, 2025
Axogen (AXGN) Q3 2024: 18% Revenue Growth Signals Execution Strength as BLA Milestone Sets Up 12-Year Exclusivity Path
November 07, 2024
Axogen (AXGN) Q2 2024: Core Accounts Hit 412 as Nerve Repair Penetration Accelerates
August 08, 2024
Axogen (AXGN) Q1 2024: Core Accounts Drive 13% Growth as Nerve Protection Portfolio Expands
May 02, 2024
Axogen (AXGN) Q4 2023: Scheduled Procedures Surge 25%, Core Account Penetration Deepens
March 05, 2024
20
Axogen (AXGN) Q3 2023: Core Accounts Expand 12% as Scheduled Procedures Surge
November 07, 2023
Axogen (AXGN) Q2 2023: Scheduled Procedures Surge 20%, Shifting Revenue Mix and Margin Dynamics
August 07, 2023
Axogen (AXGN) Q1 2023: Core Accounts Up 23%, Deepening Nerve Repair Penetration
May 09, 2023
Axogen (AXGN) Q4 2022: Core Account Penetration Rises 18% as Rep Productivity Drives Growth
March 14, 2023

Browse all companies